Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects 18 years and older~2. Relapsed or refractory multiple myeloma defined as:~   Parts A, B and C:~   (i) Failure of at least 2 previous therapies which must have included an immunomodulatory agent and a proteasome inhibitor (either together or part of different therapies) (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma~   Part D:~   (i) At least 2 previous therapies including lenalidomide and a proteasome inhibitor (ii) All subjects must have documented progression during or within 60 days after their last prior therapy for multiple myeloma~   Part E:~   (i) Received at least one previous therapy (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma~3. Presence of serum M-protein ≥ 0.5 g per 100 mL (≥ 5 g/L) and / or urine M-protein ≥ 200 mg per 24-hour period~4. Absolute neutrophil count (ANC) ≥ 1,000 / mm3~5. Haemoglobin ≥ 8 g/dL~6. Ability to comply with all study related procedures, medication use and evaluations~Exclusion Criteria:~1. Primary refractory multiple myeloma~2. History of significant cerebrovascular disease or sensory or motor neuropathy of toxicity grade 3 or higher~3. Treatment with systemic investigational agent within 28 days prior to first study treatment~4. Solitary plasmacytoma or plasma cell leukaemia~5. Previous allogenic stem cell transplant (SCT)~6. Prior therapy with other monoclonal antibodies targeting the CD38 antigen or prior therapy with other IgG monoclonal antibodies within 3 months prior to first study treatment, or IgM monoclonal antibodies within 1 month prior to first study treatment~7. Active systemic infection~8. Systemic disease preventing study treatment~9. Multiple myeloma with central nervous system (CNS) involvement~10. Previous treatment with cytotoxic chemotherapy or large field radiotherapy or other myeloma specific therapy within 28 days prior to first study treatment (radiation to a single site as concurrent therapy is allowed)~11. Significant uncontrolled cardiovascular disease or cardiac insufficiency (New York Heart Association \[NYHA\] classes III, IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 dose escalation (Type: EXPERIMENTAL): Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment.
- Phase 2a confirmatory cohorts (Type: EXPERIMENTAL): Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).